Artelo Biosciences Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist

This Artelo Biosciences Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects organization pipeline records, transaction precedents and financial-report signals; Current Awareness MCP tests for recent-event context. The output is a practical partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.

Decision date: 1 September 2026. This is a screening memorandum, not legal, medical, patent or investment advice. “Not returned” means the searched MCP result did not supply a strictly usable record and must not be read as evidence of absence.

Executive BD thesis

The organization pipeline lookup returned 5 records associated with Artelo Biosciences. The first-pass priority is ART27.13, with the highest returned status summarized as Phase 2. The partnering case should focus on a bounded asset, indication and territory rather than a generic platform pitch. The evidence supports targeted outreach, but ownership, development status and available rights require direct confirmation before economics are proposed.

Recommendation: ADVANCE A TARGETED, CONFIRMATION-LED OUTREACH. Lead with the specific evidence returned below, identify the unresolved rights questions, and make the first meeting a diligence gate rather than an economics discussion.

Partnering shortlist

The shortlist is a decision aid, not a ranking of scientific quality. A later-stage program may create faster commercial leverage but carry more territorial and lifecycle encumbrances; an early program may offer broader deal flexibility but require a larger evidence-generation commitment. The first call should therefore confirm the decision owner, rights map, active development plan, desired partner contribution and timing of the next value inflection.

Pipeline and evidence-package read-through

For each returned asset, the minimum evidence package should include current ownership, chain of title, target and mechanism rationale, indication selection, development stage, available pharmacology and safety evidence, manufacturing assumptions, regulatory interactions and the next decision-enabling readout. Where a field was not returned, the gap is an explicit diligence request rather than a negative conclusion.

ART27.13: the highest returned status is Phase 2 in Cachexia. Returned geographies include United Kingdom. Confirm whether these records reflect current active development and whether regional or indication-specific rights remain available.

ART-2612: the highest returned status is Phase 1 in Peripheral Nervous System Diseases. Returned geographies include United States. Confirm whether these records reflect current active development and whether regional or indication-specific rights remain available.

SBFI-103: the highest returned status is Preclinical in Anxiety Disorders. Returned geographies include United States. Confirm whether these records reflect current active development and whether regional or indication-specific rights remain available.

ART26.11: the highest returned status is Preclinical in an indication not returned. Returned geographies include United States. Confirm whether these records reflect current active development and whether regional or indication-specific rights remain available.

Cannabidiol/Tetremethylpyrazine: the highest returned status is Preclinical in Depressive Disorder. Returned geographies include United States. Confirm whether these records reflect current active development and whether regional or indication-specific rights remain available.

Deal precedent

Deal values are comparable only after normalizing stage, territory, option mechanics, development obligations, cost sharing, control rights, royalties, milestones and the probability of success. The practical use of precedent is to shape questions and structures, not to copy a headline number.

Financial and current-awareness signals

ARTELO BIOSCIENCES, INC. - 2020 Quarterly report: ARTELO BIOSCIENCES, INC. - 2020 Quarterly report Table of Contents Since our inception, we have used substantial amounts of cash to fund our operations and expect our expenses to increase substantially in the foreseeable future as developing our product candidates and conducting clinical trials will require substantial amounts of capital. We will also require a significant additional amount of capital to commercialize any products that are approved in the future. Our current financial resources are limited. We will need to raise additional funds in the near future in order to satisfy our working capital and capital expenditure requirements. We may raise additional funds through public or pri

ARTELO BIOSCIENCES, INC. - 2022 Quarterly report: ARTELO BIOSCIENCES, INC. - 2022 Quarterly report Artelo Biosciences, Inc.'s cash flow activities are summarized as follows. Operating Activities yielded a net loss of $1,965 and $1,695 in the two respective periods (Col2 and Col5), with adjustments to reconcile net loss to net cash used in operating activities including stock-based compensation of $624 and $530, a net change in fair value of marketable securities of $20 and -$1, and non-cash lease expense of $7 and $0. Changes in operating assets and liabilities impacted cash flow, notably with prepaid expenses and other current assets decreasing by $594 and increasing by $58, and accounts payable and accrued liabilities decreasing by $160 a

ARTELO BIOSCIENCES, INC. - 2021 Quarterly report: ARTELO BIOSCIENCES, INC. - 2021 Quarterly report Background Artelo Biosciences, Inc.'s financial summary for the years 2021 and 2020, along with the change between the two periods, is as follows. In terms of cash flows, the company utilized $1,926 thousand in operating activities in 2021, a decrease from the $1,320 thousand used in 2020, reflecting a year-over-year reduction of $606 thousand. Conversely, cash flows used in investing activities remained constant at $8,878 thousand in both years, with no change reported. In contrast, financing activities provided significantly more cash in 2021, with $18,262 thousand, compared to $6,579 thousand in 2020, resulting in an increase of $11,683 tho

These signals may indicate financing needs, portfolio prioritization or collaboration appetite, but each filing must be checked for exact entity identity and reporting period before it is used in outreach.

The Current Awareness search did not return a strictly company-matched recent event retained for Artelo Biosciences. Treat recent-event context as unconfirmed and verify company announcements, trial updates, financings, leadership changes and partnering disclosures before outreach.

IP-risk and rights diligence

• Ownership: confirm the current legal owner, inventors, assignments and any university, founder or prior-employer rights.
• Patent scope: map composition, method-of-use, formulation, delivery, biomarker, combination and manufacturing claims by territory.
• Existing obligations: review licenses, options, liens, grants, covenants, field restrictions, sublicensing economics and change-of-control provisions.
• Freedom to operate: identify blocking third-party claims and distinguish patentability from commercial freedom to operate.
• Data and materials: confirm rights to datasets, samples, vectors, cell lines, software, know-how and regulatory submissions required for the proposed transaction.

IP-risk labels in this report are triage prompts. A transaction team should commission counsel-led claim-charting and ownership review before exclusivity, option exercise or signing.

Outreach sequence and diligence gates

1. Send a narrow hypothesis tied to one asset or workstream, one territory and one partner contribution.
2. Confirm the BD decision owner, active program status, ownership and available rights before discussing valuation.
3. Request the minimum evidence package: non-confidential deck, target product profile, development plan, data cut, regulatory history, CMC status, patent schedule and existing obligations.
4. Choose a structure that matches evidence maturity: research collaboration, option, regional license, co-development, commercialization or asset acquisition.
5. Set an explicit diligence gate for scientific replication, IP review, regulatory feasibility, manufacturing readiness and commercial assumptions.

The outreach rationale should explain why the proposed partner is additive now: a missing geography, a development capability, a biomarker or trial network, manufacturing capacity, regulatory experience, commercial infrastructure or non-dilutive evidence generation. Generic platform enthusiasm is not enough.

Decision memo

Advance targeted outreach to Artelo Biosciences with confirmation gates. The MCP evidence supports a focused first conversation around ART27.13, or an organization-level rights confirmation if no usable asset row was returned. The meeting objective is to validate owner, stage, evidence package, IP position, available rights and transaction intent. Proceed to economics only after those fields reconcile across company-provided materials and independent diligence.

Method and limitations

This report chains organization_pipeline_fetch, drug_deal_search, financial_report_search and news_search. English fields were used for publication. Similar-company financial or news results were excluded when the entity could not be strictly matched. Returned records may be incomplete, historical or associated with a successor, affiliate or prior owner; all material facts require confirmation. The report is designed for BD triage and prioritization, not final diligence.

Build the next company, asset or indication screen with PatSnap Life Sciences MCP servers.